Association between CYP3A4 , CYP3A5 and ABCB1 Genotype and Tacrolimus Treatment Outcomes Among Allogeneic HSCT Patients-Reference-Cited by-同舟云学术

Association between CYP3A4 , CYP3A5 and ABCB1 Genotype and Tacrolimus Treatment Outcomes Among Allogeneic HSCT Patients

Published:2024-01 Issue:1 Volume:25 Page:29-40
ISSN:1462-2416
Container-title:Pharmacogenomics
language:en
Short-container-title:Pharmacogenomics

Author:

Ho Teresa T¹²^ORCID,Perkins Janelle B¹^ORCID,Gonzalez Rebecca³⁴,Hicks James Kevin²,Martinez Ronald Alvarez¹,Duranceau Katie¹,North Brianna¹,Kim Jongphil⁵^ORCID,Teer Jamie K⁵^ORCID,Yao Jiqiang⁵^ORCID,Yoder Sean J⁶,Nishihori Taiga³^ORCID,Bejanyan Nelli³^ORCID,Pidala Joseph³,Elmariah Hany³^ORCID

Affiliation:

1. Department of Pharmacotherapeutics & Clinical Research, University of South Florida Taneja College of Pharmacy, Tampa, FL 33612, USA

2. Department of Pathology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA

3. Department of Blood & Marrow Transplant & Cellular Immunotherapy (BMT CI), H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA

4. Department of Pharmacy, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA

5. Department of Biostatistics & Bioinformatics, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA

6. Molecular Genomics Core, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA

Funder

Moffitt Cancer Center's Pre-clinical Trial Funding Opportunity

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.2217/pgs-2023-0204

Reference46 articles.

1. HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide

2. Relationship of tacrolimus (FK506) whole blood concentrations and efficacy and safety after HLA-identical sibling bone marrow transplantation

3. Practical considerations in the use of tacrolimus for allogeneic marrow transplantation

4. Low mean post-transplantation tacrolimus levels in weeks 2–3 correlate with acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation from related and unrelated donors

5. Higher tacrolimus concentrations early after transplant reduce the risk of acute GvHD in reduced-intensity allogeneic stem cell transplantation